ClinicalTrials.gg
CompletedNCT02261285Updated May 6, 2024Results posted

ONO-4538 Phase I Study in Patients With Solid Tumor

A Phase 1 interventional study of ONO-4538 in Advanced Solid Tumors and Recurrent Solid Tumors, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 5 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.

02

Conditions studied

  • Advanced Solid Tumors
  • Recurrent Solid Tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 20 years of age
  • or cytologically confirmed solid tumor
  • Patients with advanced or recurrent solid tumors who are or intolerant to standard therapy or for whom no appropriate treatment is available
  • Performance Status is 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Current or prior severe to another antibody product
  • Multiple primary cancers
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    ONO-4538 1mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose

    Drug: ONO-4538

  • Experimental
    ONO-4538 3mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose

    Drug: ONO-4538

  • Experimental
    ONO-4538 10mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose

    Drug: ONO-4538

Interventions

06

What researchers measure

Primary outcomes

  1. PK Outcome: Cmax of ONO-4538

    Cmax was the maximum serum concentration of ONO-4538 after the single administration.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.

  2. PK Outcome: Tmax of ONO-4538

    Tmax was the time to reach the Cmax.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.

  3. AUC21day

    AUC21day was the area under serum concentration-time curve of ONO-4538 from day 0 to day 21 (last measurement).

    Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.

  4. AUCinf

    AUCinf was the area under serum concentration-time curve of ONO-4538 extrapolated to infinity.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.

  5. T1/2

    T1/2 was the elimination half-life of serum concentration of ONO-4538.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.

Secondary outcomes

  1. Safety Outcome: The Number of Subjects With Overall Adverse Events

    Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of investigational product that first appeared following exposure to investigational product or any event already present that worsened relative to the pre-treatment state following exposure to investigational product.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase.

  2. Safety Outcome: The Number of Deaths

    Number of subjects with TEAEs leading to death.

    Time frame: 3 weeks: from the start of administration to the end of treatment phase.

07

Results

Posted Apr 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
Started666
Completed665
Not completed001
Withdrew: Disease progression001

Outcome measures

PrimaryPK Outcome: Cmax of ONO-4538

Cmax was the maximum serum concentration of ONO-4538 after the single administration.

Time frame:
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Reported as:
Mean · µg/mL
PK Outcome: Cmax of ONO-4538
µg/mLONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
PK Outcome: Cmax of ONO-453826.0 ± 4.2964.3 ± 22.5242.0 ± 66.7
PrimaryPK Outcome: Tmax of ONO-4538

Tmax was the time to reach the Cmax.

Time frame:
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Reported as:
Median · hours
PK Outcome: Tmax of ONO-4538
hoursONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
PK Outcome: Tmax of ONO-45383.02 (1.07 to 9.00)3.00 (1.00 to 8.78)2.99 (1.00 to 8.62)
PrimaryAUC21day

AUC21day was the area under serum concentration-time curve of ONO-4538 from day 0 to day 21 (last measurement).

Time frame:
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Reported as:
Mean · µg*h/mL
AUC21day
µg*h/mLONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
AUC21day5110 ± 95212200 ± 206038700 ± 14200
PrimaryAUCinf

AUCinf was the area under serum concentration-time curve of ONO-4538 extrapolated to infinity.

Time frame:
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Reported as:
Mean · µg*h/mL
AUCinf
µg*h/mLONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
AUCinf9180 ± 314022800 ± 1000068100 ± 34700
PrimaryT1/2

T1/2 was the elimination half-life of serum concentration of ONO-4538.

Time frame:
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Reported as:
Mean · days
T1/2
daysONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
T1/218.3 ± 6.9719.1 ± 10.015.0 ± 7.86
SecondarySafety Outcome: The Number of Subjects With Overall Adverse Events

Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of investigational product that first appeared following exposure to investigational product or any event already present that worsened relative to the pre-treatment state following exposure to investigational product.

Time frame:
3 weeks: from the start of administration to the end of treatment phase.
Reported as:
Number · participants
Safety Outcome: The Number of Subjects With Overall Adverse Events
participantsONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
Safety Outcome: The Number of Subjects With Overall Adverse Events545
SecondarySafety Outcome: The Number of Deaths

Number of subjects with TEAEs leading to death.

Time frame:
3 weeks: from the start of administration to the end of treatment phase.
Reported as:
Count of participants · Participants
Safety Outcome: The Number of Deaths
ParticipantsONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
Safety Outcome: The Number of Deaths101

Adverse events

Collected over 3 weeks: from the start of administration to the end of treatment phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ONO-4538 1 mg/kg1/6 (16.7%)1/6 (16.7%)5/6 (83.3%)
ONO-4538 3 mg/kg0/6 (0%)0/6 (0%)4/6 (66.7%)
ONO-4538 10 mg/kg1/6 (16.7%)1/6 (16.7%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
Blood bilirubin increasedInvestigations1/60/61/6
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/61/6
Most frequent other events
Showing 10 of 32
Most frequent other events
EventONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kg
AnaemiaBlood and lymphatic system disorders1/60/63/6
Decreased appetiteMetabolism and nutrition disorders0/61/63/6
PyrexiaGeneral disorders1/60/62/6
Vertigo positionalEar and labyrinth disorders0/60/61/6
HyperthyroidismEndocrine disorders1/60/60/6
Autoimmune thyroiditisEndocrine disorders1/60/60/6
Ulcerative keratitisEye disorders0/60/61/6
AscitesGastrointestinal disorders1/60/60/6
ConstipationGastrointestinal disorders0/60/61/6
NauseaGastrointestinal disorders0/60/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
Median44.5 (36 to 74)63.0 (49 to 70)52.5 (27 to 84)56.0 (27 to 84)
Age, Customized
Age, Customized(Participants)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
<65 years43411
>=65-<75 years2316
>=75 years0011
Sex: Female, Male
Sex: Female, Male(Participants)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
Female51410
Male1528
Region of Enrollment
Region of Enrollment(participants)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
South Korea66618
Height
Height(Centimeter)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
Median156.60 (150.0 to 172.1)161.90 (151.0 to 173.0)161.35 (157.5 to 174.0)160.85 (150.0 to 174.0)
Weight
Weight(Kilogram)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
Median56.75 (48.2 to 78.5)63.40 (47.0 to 75.0)57.50 (49.8 to 68.2)59.25 (47.0 to 78.5)
BMI
BMI(Kilogram per square meter)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
Median22.62 (19.9 to 28.0)23.26 (18.9 to 32.9)21.55 (19.3 to 25.8)22.57 (18.9 to 32.9)
Performance status (Eastern Cooperative Oncology Group)
Performance status (Eastern Cooperative Oncology Group)(Participants)ONO-4538 1 mg/kgONO-4538 3 mg/kgONO-4538 10 mg/kgTotal
PS 04138
PS 125310

4 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • Seongnam-si Clinical Site 105
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Seoul Clinical Site 101
    Seoul, Korea, Republic of
  • Seoul Clinical Site 102
    Seoul, Korea, Republic of
  • Seoul Clinical Site 103
    Seoul, Korea, Republic of
  • Seoul Clinical Site 104
    Seoul, Korea, Republic of
09

References and documents

Publications

  • Lee KW, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, Kim ST, Oh DY, Bang YJ. Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. Oncologist. 2018 Feb;23(2):155-e17. doi: 10.1634/theoncologist.2017-0528. Epub 2017 Nov 20. PubMed 29158363 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Dec 2014, 2 months.

Results were first posted in Apr 2024, 9 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 10, 2014
StartActual
Oct 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Apr 16, 2024
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02261285
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Oct 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Apr 16, 2024
Last update
May 6, 2024

Study contacts

Mitsunobu Tanimoto
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion